Company Description
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe.
The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
| Country | Ireland |
| Founded | 1992 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 401 |
| CEO | John Gillard |
Contact Details
Address: IDA Business Park Bray, A98 H5C8 Ireland | |
| Phone | 353 1 276 9800 |
| Website | trinitybiotech.com |
Stock Details
| Ticker Symbol | TRIB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000888721 |
| CUSIP Number | 896438306 |
| ISIN Number | US8964385046 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| John Gillard | President, Chief Executive Officer, Company Secretary and Director |
| Ronan O'Caoimh A.C.A. | Founder, Director and Executive Advisor |
| Dr. James Walsh Ph.D. | Executive Director of Business Development and Executive Director |
| Susan O'Connor | Interim Chief Financial Officer |
| Jacqueline O'Neill | Director of Operations |
| Louise Tallon | Chief Accounting Officer |
| Dr. Gary Keating Ph.D. | Chief Technology Officer |
| Eibhlin Kelly | Chief Information Officer |
| Colm Molloy | Group Director of Human Resources and Culture |
| Adrian Donohue | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2025 | 20-F | Annual and transition report of foreign private issuers |
| May 15, 2025 | 6-K | Report of foreign issuer |
| Apr 30, 2025 | NT 20-F | Notification of inability to timely file Form 20-F |
| Apr 4, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 424B3 | Prospectus |
| Mar 28, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | UPLOAD | Filing |
| Mar 25, 2025 | SCHEDULE 13D/A | Filing |
| Mar 21, 2025 | F-3 | Filing |
| Mar 14, 2025 | 6-K | Report of foreign issuer |